Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of fludarabine and
cytarabine can help to control Acute Myelogenous Leukemia (AML), High-Risk Myelodysplastic
Syndrome (MDS) or Chronic Myeloid Leukemia (CML) in myeloid blast crisis. The safety of this
drug combination will also be studied.